600062 华润双鹤
已收盘 03-27 15:00:00
资讯
新帖
简况
华润医药(03320)附属华润双鹤发行不超10亿元公司债券
智通财经 · 03-26 19:03
华润医药(03320)附属华润双鹤发行不超10亿元公司债券
每周股票复盘：华润双鹤（600062）2025年净利增1.18%
证券之星 · 03-22
每周股票复盘：华润双鹤（600062）2025年净利增1.18%
华润双鹤：A股每股拟派发现金红利0.379元
证券日报 · 03-19
华润双鹤：A股每股拟派发现金红利0.379元
华润双鹤(600062.SH)发布2025年度业绩，归母净利润16.47亿元，同比增长1.18%
智通财经 · 03-19
华润双鹤(600062.SH)发布2025年度业绩，归母净利润16.47亿元，同比增长1.18%
华润双鹤(600062.SH)：丙戊酸钠口服溶液获得药品注册证书
智通财经 · 03-17
华润双鹤(600062.SH)：丙戊酸钠口服溶液获得药品注册证书
每周股票复盘：华润双鹤（600062）拟注销174,998股限制性股票
证券之星 · 03-15
每周股票复盘：华润双鹤（600062）拟注销174,998股限制性股票
华润双鹤（600062）披露召开2025年度业绩说明会公告，3月12日股价上涨0.33%
证券之星 · 03-12
华润双鹤（600062）披露召开2025年度业绩说明会公告，3月12日股价上涨0.33%
每周股票复盘：华润双鹤（600062）醋酸钠林格注射液获准上市
证券之星 · 03-08
每周股票复盘：华润双鹤（600062）醋酸钠林格注射液获准上市
华润双鹤最新公告：全资子公司醋酸钠林格注射液获得药品注册证书
证券之星 · 03-06
华润双鹤最新公告：全资子公司醋酸钠林格注射液获得药品注册证书
每周股票复盘：华润双鹤（600062）平衡盐冲洗液获注册证
证券之星 · 03-01
每周股票复盘：华润双鹤（600062）平衡盐冲洗液获注册证
华润双鹤（600062）披露通过GMP符合性检查公告，2月26日股价下跌0.16%
证券之星 · 02-26
华润双鹤（600062）披露通过GMP符合性检查公告，2月26日股价下跌0.16%
华润双鹤最新公告：部分药品在国家组织集采药品协议期满品种接续采购中拟中选
证券之星 · 02-10
华润双鹤最新公告：部分药品在国家组织集采药品协议期满品种接续采购中拟中选
每周股票复盘：华润双鹤（600062）拟组建营销管理中心
证券之星 · 02-08
每周股票复盘：华润双鹤（600062）拟组建营销管理中心
华润双鹤（600062）披露关于组建营销管理中心的议案，2月5日股价上涨0.38%
证券之星 · 02-05
华润双鹤（600062）披露关于组建营销管理中心的议案，2月5日股价上涨0.38%
每周股票复盘：华润双鹤（600062）获准发行30亿公司债
证券之星 · 02-01
每周股票复盘：华润双鹤（600062）获准发行30亿公司债
华润双鹤（600062）披露全资子公司复方醋酸钠林格注射液获药品注册证书，1月28日股价上涨0.32%
证券之星 · 01-28
华润双鹤（600062）披露全资子公司复方醋酸钠林格注射液获药品注册证书，1月28日股价上涨0.32%
华润双鹤最新公告：公司公开发行公司债券获得中国证监会批复
证券之星 · 01-26
华润双鹤最新公告：公司公开发行公司债券获得中国证监会批复
华润双鹤（600062）披露2026年预计发生日常关联交易公告，1月23日股价上涨0.54%
证券之星 · 01-23
华润双鹤（600062）披露2026年预计发生日常关联交易公告，1月23日股价上涨0.54%
每周股票复盘：华润双鹤（600062）DC6001片获FDA临床试验许可
证券之星 · 01-18
每周股票复盘：华润双鹤（600062）DC6001片获FDA临床试验许可
华润双鹤（600062）披露拟在珠海华润银行开展多项金融业务，1月15日股价下跌0.27%
证券之星 · 01-15
华润双鹤（600062）披露拟在珠海华润银行开展多项金融业务，1月15日股价下跌0.27%
加载更多
公司概况
公司名称：
华润双鹤药业股份有限公司
所属行业：
医药制造业
上市日期：
1997-05-22
主营业务：
华润双鹤药业股份有限公司的主营业务是玻纤及其制品。公司的主要产品是缬沙坦、氨氯地平、普瑞巴林、氨苯蝶啶、喷他佐辛、匹伐他汀、素钠、依诺肝素原料、辅酶Q10、S-Na盐。0号、压氏达、穗悦、贝奇灵、糖适平、卜可、冠爽、珂立苏、诺百益、小儿复方氨基酸注射液(19AA-I)、基础输液、BFS等产品获评中国化学制药行业各细分领域优秀产品品牌。
发行价格：
6.69
{"stockData":{"symbol":"600062","market":"SH","secType":"STK","nameCN":"华润双鹤","latestPrice":18.49,"timestamp":1774594800000,"preClose":18.07,"halted":0,"volume":11181225,"delay":0,"changeRate":0.0232,"floatShares":1033000000,"shares":1039000000,"eps":1.6043,"marketStatus":"已收盘","change":0.42,"latestTime":"03-27 15:00:00","open":17.97,"high":18.59,"low":17.95,"amount":205000000,"amplitude":0.0354,"askPrice":18.5,"askSize":660,"bidPrice":18.49,"bidSize":166,"shortable":0,"etf":0,"ttmEps":1.6043,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774834200000},"marketStatusCode":5,"adr":0,"adjPreClose":18.07,"symbolType":"stock","openAndCloseTimeList":[[1774575000000,1774582200000],[1774587600000,1774594800000]],"highLimit":19.88,"lowLimit":16.26,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1038582511,"isCdr":false,"pbRate":1.65,"roa":"--","peRate":11.525276,"roe":"14.86%","epsLYR":1.5949,"committee":-0.40859,"marketValue":19203000000,"turnoverRate":0.0108,"status":0,"floatMarketCap":19100000000},"requestUrl":"/m/hq/s/600062","defaultTab":"news","newsList":[{"id":"2622519668","title":"华润医药(03320)附属华润双鹤发行不超10亿元公司债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2622519668","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622519668?lang=zh_cn&edition=full","pubTime":"2026-03-26 19:03","pubTimestamp":1774523025,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药(03320)发布公告，公司非全资附属公司华润双鹤药业股份有限公司(华润双鹤)已于中国向合资格投资者发行首期公司债券(2026年公司债券)，本金总额不超过人民币10亿元，期限为3年，年息率为1.65%。发行首期2026年公司债券的所得款项净额将用于偿还计息债务及补充营运资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1570","BK0175","03320","BK0010","BK0239","BK1191","BK0028","600062","BK0188","BK0185"],"gpt_icon":0},{"id":"2621796250","title":"每周股票复盘：华润双鹤（600062）2025年净利增1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621796250","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621796250?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:14","pubTimestamp":1774116850,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，华润双鹤报收于18.65元，较上周的18.22元上涨2.36%。本周，华润双鹤3月20日盘中最高价报18.88元。本周关注点来自业绩披露要点：华润双鹤2025年归母净利润16.47亿元，同比上升1.18%。股本股东变化截至2026年2月28日，华润双鹤股东户数为5.46万户，较2025年12月31日减少1089户，减幅1.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0175","BK0028","BK0010","600062","BK0185","BK0239"],"gpt_icon":0},{"id":"2620322990","title":"华润双鹤：A股每股拟派发现金红利0.379元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620322990","media":"证券日报 ","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620322990?lang=zh_cn&edition=full","pubTime":"2026-03-19 21:41","pubTimestamp":1773927660,"startTime":"0","endTime":"0","summary":"证券日报网讯 3月19日，华润双鹤发布公告称，公司董事会审议通过2025年度利润分配方案，拟向全体股东每10股派发现金红利3.79元（含税），即A股每股拟派发现金红利0.379元（含税）。本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期将在权益分派实施公告中明确。该方案尚需提交股东会审议。（文章来源：证券日报）\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-19/doc-inhrpspu1404738.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-19/doc-inhrpspu1404738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159982","BK0028","399300","600062","BK0239","BK0175","BK0188","BK0185","BK0010"],"gpt_icon":0},{"id":"2620414412","title":"华润双鹤(600062.SH)发布2025年度业绩，归母净利润16.47亿元，同比增长1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620414412","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620414412?lang=zh_cn&edition=full","pubTime":"2026-03-19 18:52","pubTimestamp":1773917547,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤 发布2025年年度报告，报告期内，公司实现营业收入110.01亿元，同比下降1.88%。实现归属于上市公司股东的净利润16.47亿元，同比增长1.18%。拟向全体股东每10股派发现金红利3.79元(含税)。专科业务收入30.5亿元。抗病毒领域，治疗带状疱疹的抗病毒药溴夫定(吉时达)收入过亿，同比增长超350%。抗凝领域，依诺肝素钠注射液收入同比增长27%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600062"],"gpt_icon":0},{"id":"2620558440","title":"华润双鹤(600062.SH)：丙戊酸钠口服溶液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2620558440","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620558440?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:08","pubTimestamp":1773738530,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 华润双鹤(600062.SH)发布公告，近日，公司控股子公司湖南省湘中制药有限公司(以下简称“湘中制药”)收到了国家药品监督管理局(以下简称“国家药监局”)颁发的丙戊酸钠口服溶液《药品注册证书》。该药品获得《药品注册证书》，将进一步丰富公司产品线，有助于提升公司产品的市场竞争力，并为后续其他产品研发积累了宝贵的经验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)：丙戊酸钠口服溶液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0188","BK0028","BK0175","BK0010","BK0185","600062"],"gpt_icon":0},{"id":"2619178829","title":"每周股票复盘：华润双鹤（600062）拟注销174,998股限制性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2619178829","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619178829?lang=zh_cn&edition=full","pubTime":"2026-03-15 02:34","pubTimestamp":1773513252,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，华润双鹤报收于18.22元，较上周的18.2元上涨0.11%。本周，华润双鹤3月13日盘中最高价报18.35元。公司公告汇总：华润双鹤将于2026年3月20日召开2025年度业绩说明会。公司公告汇总北京市中伦律师事务所就华润双鹤药业股份有限公司2021年限制性股票激励计划部分限制性股票回购注销实施出具法律意见书。华润双鹤药业股份有限公司因3名激励对象不再符合激励条件，拟回购注销其已获授但尚未解除限售的限制性股票共计174,998股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000692.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0175","BK0010","600062","BK0185"],"gpt_icon":0},{"id":"2618413018","title":"华润双鹤（600062）披露召开2025年度业绩说明会公告，3月12日股价上涨0.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618413018","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618413018?lang=zh_cn&edition=full","pubTime":"2026-03-12 22:38","pubTimestamp":1773326298,"startTime":"0","endTime":"0","summary":"截至2026年3月12日收盘，华润双鹤报收于18.23元，较前一交易日上涨0.33%，最新总市值为189.37亿元。该股当日开盘18.18元，最高18.24元，最低18.12元，成交额达8560.74万元，换手率为0.46%。华润双鹤近日发布《关于召开2025年度业绩说明会的公告》。公告显示，公司将于2026年3月20日15:00至17:10召开2025年度业绩说明会，介绍公司2025年度经营成果和财务状况。投资者可于2026年3月18日16:00前通过指定网址、二维码或公司邮箱mss@dcpc.com提交问题。说明会后公司将披露会议召开情况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200039018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","600062","BK0010","BK0185","BK0188","BK0175"],"gpt_icon":0},{"id":"2617366871","title":"每周股票复盘：华润双鹤（600062）醋酸钠林格注射液获准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2617366871","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617366871?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:27","pubTimestamp":1772908030,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，华润双鹤报收于18.2元，较上周的18.4元下跌1.09%。本周关注点公司公告汇总：全资子公司醋酸钠林格注射液获药品注册证书公司公告汇总：该药品注册分类为化学药品3类，视同通过一致性评价公司公告汇总：截至公告日，该项目累计研发投入146.64万元公司公告汇总华润双鹤全资子公司西安京西双鹤药业有限公司研发的醋酸钠林格注射液于2026年2月25日获得国家药监局批准上市，注册分类为化学药品3类，视同通过一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062","BK0239","BK0185","BK0010","BK0028","BK0175","BK0188"],"gpt_icon":0},{"id":"2617168627","title":"华润双鹤最新公告：全资子公司醋酸钠林格注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2617168627","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617168627?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:30","pubTimestamp":1772789445,"startTime":"0","endTime":"0","summary":"华润双鹤(600062.SH)公告称，公司全资子公司西安京西双鹤药业有限公司收到国家药监局颁发的醋酸钠林格注射液《药品注册证书》。该药品用于循环血容量及组织间液减少时细胞外液的补充，代谢性酸中毒的纠正。京西双鹤于2023年11月启动该药品的仿制药研发工作，于2024年9月提交上市许可申请，并于2026年2月获得批准上市。根据国家相关政策规定，本次获得《药品注册证书》视同通过一致性评价。截至公告日，公司针对该药品累计研发投入为146.64万元。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600028516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0175","BK0010","600062","BK0185"],"gpt_icon":0},{"id":"2616784393","title":"每周股票复盘：华润双鹤（600062）平衡盐冲洗液获注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2616784393","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616784393?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:00","pubTimestamp":1772301642,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，华润双鹤报收于18.4元，较上周的18.31元上涨0.49%。本周，华润双鹤2月26日盘中最高价报18.58元。来自公司公告汇总：固体制剂、注射剂等多条生产线通过GMP符合性检查。来自公司公告汇总：平衡盐冲洗液国内市场规模达5,585万元，已有多家企业布局。华润双鹤全资子公司西安京西双鹤药业有限公司研发的平衡盐冲洗液获得国家药品监督管理局颁发的药品注册证书，规格为500ml、1000ml，注册分类为化学药品3类，视同通过一致性评价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","600062","BK0010","BK0185","BK0188","BK0175"],"gpt_icon":0},{"id":"2614023937","title":"华润双鹤（600062）披露通过GMP符合性检查公告，2月26日股价下跌0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614023937","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614023937?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:49","pubTimestamp":1772117352,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘，华润双鹤报收于18.46元，较前一交易日下跌0.16%，最新总市值为191.75亿元。该股当日开盘18.53元，最高18.58元，最低18.42元，成交额达9432.26万元，换手率为0.49%。近日，华润双鹤药业股份有限公司收到北京市药品监督管理局颁发的《药品GMP符合性检查告知书》，公司固体制剂车间硬胶囊剂生产线、注射剂车间小容量注射剂K线、冻干车间半固体制剂生产线通过GMP符合性检查。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0175","600062","BK0239","BK0028","BK0185","BK0188"],"gpt_icon":0},{"id":"2610291648","title":"华润双鹤最新公告：部分药品在国家组织集采药品协议期满品种接续采购中拟中选","url":"https://stock-news.laohu8.com/highlight/detail?id=2610291648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610291648?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:27","pubTimestamp":1770715647,"startTime":"0","endTime":"0","summary":"华润双鹤(600062.SH)公告称，2026年2月9日，公司及部分下属子公司的缬沙坦氢氯噻嗪片、硝苯地平缓释片(Ⅱ)、硝苯地平控释片、厄贝沙坦分散片、依诺肝素钠注射液等药品拟中选集采药品协议期满品种接续采购，上述主要拟中选药品系公司参与本次接续采购的药品中收入规模排名前五的品种，除上述主要拟中选药品外，公司另有阿法骨化醇软胶囊等48个药品参与本次接续采购并拟中选。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000028171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0175","BK0185","600062","BK0010","BK0188"],"gpt_icon":0},{"id":"2609526859","title":"每周股票复盘：华润双鹤（600062）拟组建营销管理中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2609526859","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609526859?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:34","pubTimestamp":1770489252,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，华润双鹤报收于18.68元，较上周的18.76元下跌0.43%。本周，华润双鹤2月6日盘中最高价报18.88元。华润双鹤当前最新总市值194.04亿元，在化学制药板块市值排名26/150，在两市A股市值排名1085/5186。本周关注点公司公告汇总：华润双鹤拟组建营销管理中心，以推进营销资源整合。公司公告汇总华润双鹤第十届董事会第十七次会议于2026年2月5日以通讯方式召开，11名董事全部出席。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0185","BK0175","600062","BK0188","BK0239","BK0028"],"gpt_icon":0},{"id":"2609294309","title":"华润双鹤（600062）披露关于组建营销管理中心的议案，2月5日股价上涨0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609294309","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609294309?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:30","pubTimestamp":1770301842,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，华润双鹤报收于18.73元，较前一交易日上涨0.38%，最新总市值为194.56亿元。该股当日开盘18.69元，最高18.81元，最低18.65元，成交额达1.22亿元，换手率为0.63%。华润双鹤药业股份有限公司于2026年2月5日召开第十届董事会第十七次会议，会议通知于2026年2月2日以邮件方式发出，会议以通讯方式举行，11名董事全部出席。会议审议通过了《关于2026年境外佣金预算的议案》和《关于组建营销管理中心的议案》。两项议案均获全票通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0010","BK0185","BK0175","BK0188","600062"],"gpt_icon":0},{"id":"2608774020","title":"每周股票复盘：华润双鹤（600062）获准发行30亿公司债","url":"https://stock-news.laohu8.com/highlight/detail?id=2608774020","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608774020?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:22","pubTimestamp":1769887333,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，华润双鹤报收于18.76元，较上周的18.72元上涨0.21%。本周，华润双鹤1月27日盘中最高价报19.08元。本周关注点公司公告汇总：华润双鹤获证监会批复，同意其向专业投资者公开发行面值总额不超过30亿元的公司债券。该批复自同意注册之日起24个月内有效，公司可在注册有效期内分期发行公司债券。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0185","BK0175","600062","BK0188","BK0239","BK0028"],"gpt_icon":0},{"id":"2606102957","title":"华润双鹤（600062）披露全资子公司复方醋酸钠林格注射液获药品注册证书，1月28日股价上涨0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606102957","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606102957?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:53","pubTimestamp":1769611990,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，华润双鹤报收于18.85元，较前一交易日上涨0.32%，最新总市值为195.81亿元。该股当日开盘18.93元，最高19.03元，最低18.76元，成交额达1.78亿元，换手率为0.91%。近日，华润双鹤发布关于全资子公司西安京西双鹤药业有限公司复方醋酸钠林格注射液获得药品注册证书的公告。公告显示，西安京西双鹤药业有限公司收到国家药监局颁发的复方醋酸钠林格注射液《药品注册证书》，规格为250ml、500ml，注册分类为化学药品3类，视同通过一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800043287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0010","BK0175","BK0185","BK0239","600062","BK0188"],"gpt_icon":0},{"id":"2606216004","title":"华润双鹤最新公告：公司公开发行公司债券获得中国证监会批复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606216004","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606216004?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:19","pubTimestamp":1769422768,"startTime":"0","endTime":"0","summary":"华润双鹤(600062.SH)公告称，公司近日收到中国证监会出具的批复，同意公司向专业投资者公开发行面值总额不超过30亿元公司债券的注册申请。该批复自同意注册之日起24个月内有效，公司在注册有效期内可以分期发行公司债券。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600024827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600062","BK0175","BK0188","BK0028","BK0185","BK0010"],"gpt_icon":0},{"id":"2605440687","title":"华润双鹤（600062）披露2026年预计发生日常关联交易公告，1月23日股价上涨0.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605440687","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605440687?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:36","pubTimestamp":1769178980,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，华润双鹤报收于18.72元，较前一交易日上涨0.54%，最新总市值为194.46亿元。该股当日开盘18.66元，最高18.72元，最低18.62元，成交额达1.54亿元，换手率为0.8%。公司近日发布公告称，华润双鹤药业股份有限公司于2026年1月23日召开2026年第一次临时股东会，审议通过了关于2026年预计发生日常关联交易的议案。出席会议的股东所持有表决权股份数占公司总股本的62.8986%。涉及关联交易的议案已由控股股东及关联方回避表决。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0010","600062","BK0188","BK0028","BK0239","BK0185"],"gpt_icon":0},{"id":"2604230169","title":"每周股票复盘：华润双鹤（600062）DC6001片获FDA临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2604230169","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604230169?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:26","pubTimestamp":1768677970,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，华润双鹤报收于18.54元，较上周的18.65元下跌0.59%。本周关注点公司公告汇总：DC6001片获FDA药物临床试验默示许可，适应症为Stargardt病。公司公告汇总华润双鹤全资子公司北京双鹤润创科技有限公司申报的DC6001片已获得FDA新药临床试验默示许可，可开展临床试验。该药品适应症为Stargardt病，此前已获国家药监局临床试验批准，并于2025年11月获FDA罕见儿科疾病药物认定。目前国内已有2家生产企业获批，华润双鹤市场份额居首。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0175","BK0028","600062","BK0239","BK0188","BK0010"],"gpt_icon":0},{"id":"2603986184","title":"华润双鹤（600062）披露拟在珠海华润银行开展多项金融业务，1月15日股价下跌0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603986184","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603986184?lang=zh_cn&edition=full","pubTime":"2026-01-15 22:34","pubTimestamp":1768487655,"startTime":"0","endTime":"0","summary":"截至2026年1月15日收盘，华润双鹤报收于18.65元，较前一交易日下跌0.27%，最新总市值为193.73亿元。公司近日发布公告称，华润双鹤药业股份有限公司拟在珠海华润银行办理承兑汇票、存款、理财和融资业务，其中承兑汇票年度总额不超过2亿元，存款余额不超过3亿元，理财年度总额不超过2亿元，融资年度总额不超过3亿元。相关业务有效期分别为1年或2年，需经股东会审议批准。该事项已作为华润双鹤2026年第一次临时股东会会议文件提交审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500041125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600062","BK0010","161121","BK0028","BK0185","BK0175","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774615808149,"stockEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":-0.0179},{"period":"3month","weight":-0.0227},{"period":"6month","weight":-0.0292},{"period":"1year","weight":-0.0166},{"period":"ytd","weight":-0.012}],"compareEarnings":[{"period":"1week","weight":-0.0293},{"period":"1month","weight":-0.0555},{"period":"3month","weight":-0.0188},{"period":"6month","weight":0.0159},{"period":"1year","weight":0.1545},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润双鹤药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"54633人(较上一季度减少1.95%)","perCapita":"18907股","listingDate":"1997-05-22","address":"北京市朝阳区望京利泽东二路1号","registeredCapital":"103858万元","survey":" 华润双鹤药业股份有限公司的主营业务是玻纤及其制品。公司的主要产品是缬沙坦、氨氯地平、普瑞巴林、氨苯蝶啶、喷他佐辛、匹伐他汀、素钠、依诺肝素原料、辅酶Q10、S-Na盐。0号、压氏达、穗悦、贝奇灵、糖适平、卜可、冠爽、珂立苏、诺百益、小儿复方氨基酸注射液(19AA-I)、基础输液、BFS等产品获评中国化学制药行业各细分领域优秀产品品牌。","listedPrice":6.69},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华润双鹤,600062,华润双鹤股票,华润双鹤股票老虎,华润双鹤股票老虎国际,华润双鹤行情,华润双鹤股票行情,华润双鹤股价,华润双鹤股市,华润双鹤股票价格,华润双鹤股票交易,华润双鹤股票购买,华润双鹤股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}